Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Nock

Showing results (81-90 of 114) with videos related to

Pageof 12
Sort By:
Cancer Biotherapy & Radiopharmaceuticals|October 7, 2014
In vivo enzyme inhibition improves the targeting of [177Lu]DOTA-GRP(13-27) in GRPR-positive tumors in micePanteleimon J Marsouvanidis, Marleen Melis, Erik de Blois, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 4, 2015
Preclinical and first clinical experience with the gastrin-releasing peptide receptor-antagonist [⁶⁸Ga]SB3 and PET/CTTheodosia Maina, Hendrik Bergsma, Harshad R Kulkarni, et al.
FEMS Microbiology Ecology|June 19, 2018
Soils associated to different tree communities do not elicit predictable responses in lake bacterial community structure and functionClara Ruiz-González, Esther Archambault, Isabelle Laforest-Lapointe, et al.
Journal of Medicinal Chemistry|March 9, 2018
New Gastrin Releasing Peptide Receptor-Directed [<sup>99m</sup>Tc]Demobesin 1 Mimics: Synthesis and Comparative EvaluationBerthold A Nock, David Charalambidis, Werner Sallegger, et al.
Pharmaceutics|March 28, 2024
Amide-to-Triazole Switch in Somatostatin-14-Based Radioligands: Impact on Receptor Affinity and In Vivo StabilityXabier Guarrochena, Panagiotis Kanellopoulos, Anna Stingeder, et al.
EJNMMI Research|May 25, 2019
Instant kit preparation of <sup>68</sup>Ga-radiopharmaceuticals via the hybrid chelator DATA: clinical translation of [<sup>68</sup>Ga]Ga-DATA-TOCJean-Philippe Sinnes, Johannes Nagel, Bradley P Waldron, et al.
Pharmaceutics|March 29, 2023
[<sup>111</sup>In]In/[<sup>177</sup>Lu]Lu-AAZTA<sup>5</sup>-LM4 SST<sub>2</sub>R-Antagonists in Cancer Theranostics: From Preclinical Testing to First Patient ResultsBerthold A Nock, Panagiotis Kanellopoulos, Euy Sung Moon, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 6, 2016
Theranostic Perspectives in Prostate Cancer with the Gastrin-Releasing Peptide Receptor Antagonist NeoBOMB1: Preclinical and First Clinical ResultsBerthold A Nock, Aikaterini Kaloudi, Emmanouil Lymperis, et al.
International Journal of Cancer|May 12, 2019
Trastuzumab cotreatment improves survival of mice with PC-3 prostate cancer xenografts treated with the GRPR antagonist <sup>177</sup> Lu-DOTAGA-PEG<sub>2</sub> -RM26Bogdan Mitran, Sara S Rinne, Mark W Konijnenberg, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 30, 2011
Comparison of biological stability and metabolism of CCK2 receptor targeting peptides, a collaborative project under COST BM0607Meltem Ocak, Anna Helbok, Christine Rangger, et al.
Pageof 12

Showing results (81-90 of 114) with videos related to

Sort By:
Pageof 12
Cancer Biotherapy & Radiopharmaceuticals|October 7, 2014
In vivo enzyme inhibition improves the targeting of [177Lu]DOTA-GRP(13-27) in GRPR-positive tumors in micePanteleimon J Marsouvanidis, Marleen Melis, Erik de Blois, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 4, 2015
Preclinical and first clinical experience with the gastrin-releasing peptide receptor-antagonist [⁶⁸Ga]SB3 and PET/CTTheodosia Maina, Hendrik Bergsma, Harshad R Kulkarni, et al.
FEMS Microbiology Ecology|June 19, 2018
Soils associated to different tree communities do not elicit predictable responses in lake bacterial community structure and functionClara Ruiz-González, Esther Archambault, Isabelle Laforest-Lapointe, et al.
Journal of Medicinal Chemistry|March 9, 2018
New Gastrin Releasing Peptide Receptor-Directed [<sup>99m</sup>Tc]Demobesin 1 Mimics: Synthesis and Comparative EvaluationBerthold A Nock, David Charalambidis, Werner Sallegger, et al.
Pharmaceutics|March 28, 2024
Amide-to-Triazole Switch in Somatostatin-14-Based Radioligands: Impact on Receptor Affinity and In Vivo StabilityXabier Guarrochena, Panagiotis Kanellopoulos, Anna Stingeder, et al.
EJNMMI Research|May 25, 2019
Instant kit preparation of <sup>68</sup>Ga-radiopharmaceuticals via the hybrid chelator DATA: clinical translation of [<sup>68</sup>Ga]Ga-DATA-TOCJean-Philippe Sinnes, Johannes Nagel, Bradley P Waldron, et al.
Pharmaceutics|March 29, 2023
[<sup>111</sup>In]In/[<sup>177</sup>Lu]Lu-AAZTA<sup>5</sup>-LM4 SST<sub>2</sub>R-Antagonists in Cancer Theranostics: From Preclinical Testing to First Patient ResultsBerthold A Nock, Panagiotis Kanellopoulos, Euy Sung Moon, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 6, 2016
Theranostic Perspectives in Prostate Cancer with the Gastrin-Releasing Peptide Receptor Antagonist NeoBOMB1: Preclinical and First Clinical ResultsBerthold A Nock, Aikaterini Kaloudi, Emmanouil Lymperis, et al.
International Journal of Cancer|May 12, 2019
Trastuzumab cotreatment improves survival of mice with PC-3 prostate cancer xenografts treated with the GRPR antagonist <sup>177</sup> Lu-DOTAGA-PEG<sub>2</sub> -RM26Bogdan Mitran, Sara S Rinne, Mark W Konijnenberg, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 30, 2011
Comparison of biological stability and metabolism of CCK2 receptor targeting peptides, a collaborative project under COST BM0607Meltem Ocak, Anna Helbok, Christine Rangger, et al.
Pageof 12